Effect of Vitamin D on Symptoms of Parkinson's Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240708007

Enrollment

Registered

2024-07-08

Start date

2024-03-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#039

Interventions

Vitamin D3 2,000 IU/day for 12 weeks,Standard treatment not receive vitamin D3

Experimental Drug,No Intervention No treatment

Vitamin D,Control

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Parkinson's disease patients, age 50-80 years

Exclusion criteria

Exclusion criteria: 1. current vitamin D intake 2. patients who have kidney or ureteric stone 3. TMSE < 15 4. patients who diagnosed with osteoporosis or bone fracture

Design outcomes

Primary

Measure	Time frame
symptoms improvement 12 weeks UPDRS,Quality of life 12 weeks PDQ 39	—

Secondary

Measure	Time frame
prevalence day 0 number of patients with vitamin D deficiency	—

Countries

Thailand

Contacts

Public ContactChumpol Anamnart

Prapokklao Hospital

chumpolan@gmail.com0814306100

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Effect of Vitamin D on Symptoms of Parkinson&#039;s Disease